Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Motexafin gadolinium may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug. PURPOSE: Phase I trial to study the effectiveness of combining motexafin gadolinium with doxorubicin in treating patients who have recurrent or metastatic cancer.
Checked against the public recordLast updated Dec 17, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- University of Wisconsin, Madison
- Interventions being studied
- Drug: doxorubicin hydrochloride; Drug: motexafin gadolinium
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically confirmed advanced malignancy that is considered incurable * Recurrent or metastatic disease * Relapsed solid tumors include, but are not limited to the following sites: * Lung * Breast * Colon * Prostate * Head and neck * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * 18 and over Sex * Not specified Menopausal status * Not specified Performance status: * ECOG 0-2 Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * AST and ALT no greater than 2 times upper limit of normal Renal: * Creatinine no greater than 2.0 mg/dL Cardiovascular: * LVEF greater than 45% at rest * No prior myocardial infarction * No congestive heart failure * No clinically significant ventricular arrhythmias Other: * No history of HIV infection * No history of porphyria * No glucose-6-phosphate dehydrogenase deficiency * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 6 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 28 days since prior chemotherapy * No prior lifetime cumulative doxorubicin exposure of more than 300 mg/m\^2 * No other concurrent cytotoxic chemotherapy Endocrine therapy: * Not specified Radiotherapy: * At least 28 days since prior radiotherapy * No concurrent radiotherapy Surgery: * No concurrent surgery Other: * At least 14 days since prior multidrug resistance-modulating drugs (e.g., PSC833 or cyclosporine) * No other concurrent antineoplastic or investigational agents
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Hillman Cancer Center at University of Pittsburgh Cancer InstitutePittsburgh, Pennsylvania
- University of Wisconsin Comprehensive Cancer CenterMadison, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 17, 2019. Always confirm current availability with the study team.